Intracellular signaling pathways as a target for the treatment of rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2001-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1471-4892(01)00054-6PMID 11712756
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

  2001cited by this paper
• IL‐1‐ and TNF‐induced bone resorption is mediated by p38 mitogen activated protein kinase *

  2001cited by this paper
• The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.

  2001cited by this paper
• p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.

  2001cited by this paper
• NF-κB: a key role in inflammatory diseases

  2001cited by this paper
• Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis.

  2000cited by this paper
• Jaks and Stats as therapeutic targets

  2000cited by this paper
• Activation of osteoclasts by interleukin‐1: divergent responsiveness in osteoclasts formed in vivo and in vitro

  2000cited by this paper
• Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.

  2000cited by this paper
• Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures.

  2000cited by this paper
• Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts.

  2000cited by this paper
• Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction

  2000cited by this paper
• Deficiency of the Stress Kinase P38α Results in Embryonic Lethality

  2000cited by this paper
• Arguments for interleukin 1 as a target in chronic arthritis.

  2000cited by this paper
• Inhibition of p38 MAP kinase as a therapeutic strategy.

  2000cited by this paper
• Signalling to translational activation of tumour necrosis factor-alpha expression in human THP-1 cells.

  2000cited by this paper
• Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.

  2000cited by this paper
• Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)*

  2000cited by this paper
• SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.

  2000cited by this paper
• Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis.

  2000cited by this paper
• Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

  2000cited by this paper
• The Bone and Joint Decade 2000–2010

  2000cited by this paper
• Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

  2000cited by this paper
• Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3.

  2000cited by this paper
• Cytokines in rheumatoid arthritis: trials and tribulations.

  2000cited by this paper
• Mitogen‐activated kinase kinase kinase 1 regulates T cell receptor‐ and CD28‐mediated signaling events which lead to NF‐κB activation

  2000cited by this paper
• Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo.

  2000cited by this paper
• New inhibitors of p38 kinase

  2000cited by this paper
• The role of p38 mitogen‐activated protein kinase in IL‐6 and IL‐8 production from the TNF‐α‐ or IL‐1β‐stimulated rheumatoid synovial fibroblasts

  2000cited by this paper
• Jun N-terminal kinase in rheumatoid arthritis.

  1999cited by this paper
• MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis

  1999cited by this paper
• RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

  1999cited by this paper
• Signal transduction and transcription factors in rheumatic disease.

  1999cited by this paper
• Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

  1999cited by this paper
• Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human.

  1999cited by this paper
• Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IκB kinases (IKK-α/β) and IKK-β is a developmentally regulated protein kinase

  1999cited by this paper
• Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies.

  1999cited by this paper
• The Jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the I kappa B kinase cascade.

  1999cited by this paper
• Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.

  1999cited by this paper
• Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase*

  1998cited by this paper
• Pyrroles and other heterocycles as inhibitors of p38 kinase.

  1998cited by this paper
• Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes.

  1998cited by this paper
• NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.

  1998cited by this paper
• Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation

  1997cited by this paper
• Activation of the I k B a Kinase Complex by MEKK 1 , a Kinase of the JNK Pathway

  1997cited by this paper
• INTERLEUKIN-1β CONVERTING ENZYME INHIBITION BLOCKS PROGRESSION OF TYPE II COLLAGEN-INDUCED ARTHRITIS IN MICE

  1996cited by this paper
• Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.

  1996cited by this paper
• Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis

  1995cited by this paper
• A synthetic inhibitor of the mitogen-activated protein kinase cascade.

  1995cited by this paper
• A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

  1994cited by this paper
• Interactive effects of the tumor necrosis factor promoter and 3'-untranslated regions.

  1991cited by this paper
• Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

  1989cited by this paper
• Pathways to chronic inflammation in rheumatoid synovitis.

  1987cited by this paper
• Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

  1985cited by this paper

• In silico analysis of missense SNPs in TNFR1a and their possible therapeutic or pathogenic role in immune diseases.

  2023cites this paper
• Ubiquitination in rheumatoid arthritis.

  2020cites this paper
• 4-(Hydroxymethyl)catechol Extracted From Fungi in Marine Sponges Attenuates Rheumatoid Arthritis by Inhibiting PI3K/Akt/NF-κB Signaling

  2018cites this paper
• Anti‐inflammatory effects of ursolic acid‐3‐acetate on human synovial fibroblasts and a murine model of rheumatoid arthritis

  2017cites this paper
• Cytokine-induced apoptosis inhibitor-1 causes dedifferentiation of rabbit articular chondrocytes via the ERK-1/2 and p38 kinase pathways.

  2016cites this paper
• Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.

  2016cites this paper
• Overexpression of ADAMTS-7 leads to accelerated initiation and progression of collagen-induced arthritis in mice

  2015cites this paper
• Salvia plebeia extract inhibits the inflammatory response in human rheumatoid synovial fibroblasts and a murine model of arthritis.

  2015cites this paper
• Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease

  2014cites this paper
• Effects of low frequency cyclic mechanical stretching on osteoclastogenesis.

  2014cites this paper
• TNF-α signalling and inflammation: interactions between old acquaintances

  2013cites this paper
• Targeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles.

  2013cites this paper
• [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

  2012cites this paper
• Newer Immunosuppressive Drugs

  2012cites this paper
• Intrazelluläre Signaltransduktionswege

  2011cites this paper
• An integrative approach to structured SNP prioritization and representative snp selection for genome-wide association studies (Genom boyutunda ilişkilendirme çalışmalarında yapılandırılmış SNP önceliklendirmesi ve temsilci snp seçimi için bütünleşik bir yaklaşım)

  2011cites this paper
• The p 38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cites this paper
• The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cites this paper
• Metalloproteases as potential therapeutic targets in arthritis treatment

  2008cites this paper
• MAPKs and their relevance to arthritis and inflammation.

  2007cites this paper
• Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics

  2006cites this paper
• p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.

  2006cites this paper
• Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system.

  2005cites this paper
• MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.

  2005cites this paper
• Polyamine depletion inhibits NF-kappaB binding to DNA and interleukin-8 production in human chondrocytes stimulated by tumor necrosis factor-alpha.

  2005cites this paper
• Signal pathways underlying homocysteine-induced production of MCP-1 and IL-8 in cultured human whole blood

  2005cites this paper
• Adenovirus-mediated gene transfer of mutated IkappaB kinase and IkappaBalpha reveal NF-kappaB-dependent as well as NF-kappaB-independent pathways of HAS1 activation.

  2005cites this paper
• Pharmacological Potential of p38 MAPK Inhibitors

  2005cites this paper
• Adenovirus-mediated Gene Transfer of Mutated IκB Kinase and IκBα Reveal NF-κB-dependent as Well as NF-κB-independent Pathways of HAS1 Activation*

  2005cites this paper
• Polyamine depletion inhibits NF‐κB binding to DNA and interleukin‐8 production in human chondrocytes stimulated by tumor necrosis factor‐α

  2005cites this paper
• Novel Molecular Targets in the Search for Anti-Inflammatory Agents

  2005cites this paper
• Aggrecan degradation in health and disease

  2004cites this paper
• Upcoming biologic agents for the treatment of rheumatic diseases

  2003cites this paper
• Concomitant Recruitment of ERK1/2 and p38 MAPK Signalling Pathway Is Required for Activation of Cytoplasmic Phospholipase A2via ATP in Articular Chondrocytes*

  2003cites this paper
• p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.

  2003cites this paper
• Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy.

  2002cites this paper